Phenothiazine-Based LSD1 Inhibitor Promotes T-Cell Killing Response of Gastric Cancer Cells

LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer

(2022) Dan-Dan Shen et al.   Molecular Cancer

Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1

(2021) Xing-Jie Dai et al.   JOURNAL OF MEDICINAL CHEMISTRY

Simultaneous Inhibition of LSD1 and TGF-B Enables Eradication of Poorly Immunogenic Tumors with anti-PD-1 Treatment

(2021) Wanqiang Sheng et al.   Cancer Discovery

Lysine demethylase LSD1 delivered via small extracellular vesicles promotes gastric cancer cell stemness

(2021) Li‐Juan Zhao et al.   EMBO REPORTS

An Update of Lysine Specific Demethylase 1 Inhibitor: A Patent Review (2016-2020)

(2021) Yi-Chao Zheng et al.   Recent Patents on Anti-Cancer Drug Discovery

Annual review of lysine-specific demethylase 1 (LSD1/KDM1A) inhibitors in 2021

(2021) Yihui Song et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Exploration of 5-cyano-6-phenylpyrimidin derivatives containing an 1,2,3-triazole moiety as potent FAD-based LSD1 inhibitors

(2020) Liying Ma et al.   Acta Pharmaceutica Sinica B

Natural products as LSD1 inhibitors for cancer therapy

(2020) Yuan Fang et al.   Acta Pharmaceutica Sinica B

Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective

(2020) Xing-Jie Dai et al.   JOURNAL OF MEDICINAL CHEMISTRY

Targeting the epigenetic regulation of antitumour immunity

(2020) Simon J. Hogg et al.   NATURE REVIEWS DRUG DISCOVERY

LSD1 deletion represses gastric cancer migration by upregulating a novel miR-142-5p target protein CD9

(2020) Li-Juan Zhao et al.   PHARMACOLOGICAL RESEARCH

A Comparative Linear Interaction Energy and MM/PBSA Study on SIRT1–Ligand Binding Free Energy Calculation

(2019) Eko Aditya Rifai et al.   Journal of Chemical Information and Modeling

Derivative of 5-cyano-6-phenylpyrimidin antagonizes ABCB1- and ABCG2-mediated multidrug resistance

(2019) Jing-Quan Wang et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

LSD1/KDM1A inhibitors in clinical trials: advances and prospects

(2019) Yuan Fang et al.   Journal of Hematology & Oncology

LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade

(2018) Wanqiang Sheng et al.   CELL

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-ligand 1 Signaling Pathway

(2018) Tianyu Wang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade

(2018) Ye Qin et al.   ONCOGENE

Advances toward LSD1 inhibitors for cancer therapy

(2017) Xiaoli Fu et al.   Future Medicinal Chemistry

GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses

(2017) Zefang Tang et al.   NUCLEIC ACIDS RESEARCH

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

Design, Synthesis, and Structure–Activity Relationship of Novel LSD1 Inhibitors Based on Pyrimidine–Thiourea Hybrids As Potent, Orally Active Antitumor Agents

(2015) Li-Ying Ma et al.   JOURNAL OF MEDICINAL CHEMISTRY

Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma

(2015) Melissa M. Singh et al.   NEURO-ONCOLOGY

Synthesis and biological evaluation of coumarin–1,2,3-triazole–dithiocarbamate hybrids as potent LSD1 inhibitors

(2014) Xian-Wei Ye et al.   MedChemComm

3,5-Diamino-1,2,4-triazoles as a novel scaffold for potent, reversible LSD1 (KDM1A) inhibitors

(2014) Craig J. Kutz et al.   MedChemComm

PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data

(2013) Daniel R. Roe et al.   Journal of Chemical Theory and Computation

Triazole–Dithiocarbamate Based Selective Lysine Specific Demethylase 1 (LSD1) Inactivators Inhibit Gastric Cancer Cell Growth, Invasion, and Migration

(2013) Yi-Chao Zheng et al.   JOURNAL OF MEDICINAL CHEMISTRY

LSD1 inhibition: a therapeutic strategy in cancer?

(2012) James T Lynch et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers

(2010) Shinya Hayami et al.   INTERNATIONAL JOURNAL OF CANCER

Lysine-Specific Demethylase 1 Is Strongly Expressed in Poorly Differentiated Neuroblastoma: Implications for Therapy

(2009) J. H. Schulte et al.   CANCER RESEARCH

Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology

(2009) Soyoung Lim et al.   CARCINOGENESIS